局部进展期胃癌新辅助化疗后腹腔镜与开腹胃切除术的近期和远期结局
该回顾性队列研究纳入49例局部进展期胃癌新辅助化疗后行胃切除术的患者,比较腹腔镜组与开腹组的近期和远期结局,发现腹腔镜组术中出血量更少、住院时间更短,两组并发症率及5年无病生存率和总生存率无显著差异。
要点
- 腹腔镜组术中出血量显著少于开腹组,住院时间更短。
- 两组总体并发症率分别为10%与24%,差异无统计学意义(P=0.277)。
- 腹腔镜手术并非无病生存或总生存的独立危险因素。
核心结论
- 对于新辅助化疗后的胃癌患者,腹腔镜胃切除术可能是潜在的治疗选择,具有较高的成功率和可接受的近期及远期结局。
主要发现
- 腹腔镜组术中出血量显著少于开腹组,住院时间显著短于开腹组。
- 总体并发症率腹腔镜组为10%(2/20),开腹组为24%(7/29),P=0.277。
- 5年无病生存率腹腔镜组44.4% vs 开腹组53.3%,P=0.382;5年总生存率腹腔镜组46.9% vs 开腹组54.0%,P=0.422。
- 多因素分析显示手术方式(腹腔镜 vs 开腹)不是无病生存(P=0.645)或总生存(P=0.489)的独立危险因素。
临床怎么用
- 在新辅助化疗后的局部进展期胃癌患者中,腹腔镜胃切除术可考虑作为开腹手术的替代选择,但需结合患者具体情况和术者经验。
局限性
- 回顾性研究,样本量较小(49例),可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to investigate the short- and long-term outcomes of laparoscopic gastrectomy (LG) in patients with advanced gastric cancer following neoadjuvant chemotherapy (NAC) to determine its safety and feasibility. METHODS: We retrospectively investigated 51 patients who underwent gastrectomy for locally advanced gastric cancer [cT3-4/N1-3 or macroscopic type 3 (> 80 mm) or type 4] following NAC between November 2009 and January 2018. After excluding two patients who underwent palliative surgery due to peritoneal dissemination, 49 patients were ultimately selected for this cohort study. The patients were then divided into the LG group and open gastrectomy (OG) group, after which the clinicopathological characteristics as well as short- and long-term outcomes were examined. RESULTS: Compared with the OG group, the LG group demonstrated a significantly lower amount of intraoperative blood loss and a shorter hospital stay. The overall complication rates were 10% (2 of 20 patients) and 24% (7 of 29 patients) in the LG and OG groups (P = 0.277), respectively. No significant differences in 5-year disease-free (LG 44.4% vs. OG 53.3%; P = 0.382) or overall survival rates (LG 46.9% vs. OG 54.0%; P = 0.422) were observed between the groups. Multivariate analysis revealed that the surgical procedure (LG vs. OG) was not an independent risk factor for disease-free (P = 0.645) or overall survival (P = 0.489). CONCLUSIONS: LG may be a potential therapeutic option for patients with gastric cancer following NAC considering its high success rates and acceptable short- and long-term outcomes.
引用
- Fujisaki M, Mitsumori N, Shinohara T, et al. Short- and long-term outcomes of laparoscopic versus open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy. Surg Endosc. 2020. PMID: 32277356. doi:10.1007/s00464-020-07552-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。